Manatuck Hill Partners’s Eterna Therapeutics ERNA Stock Holding History

Manatuck Hill Partners’s Portfolio ERNA Stock Details ERNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-1	Closed	-$95K	–	93
2016 Q3	$95K	Sell	1 -1	-50%	-$97.8K	0.04%	91
2016 Q2	$258K	Sell	2 -2	-50%	-$226K	0.11%	71
2016 Q1	$261K	Hold	4	–	–	0.09%	75
2015 Q4	$300K	Hold	4	–	–	0.1%	65
2015 Q3	$628K	Hold	4	–	–	0.27%	41
2015 Q2	$436K	Hold	4	–	–	0.13%	60
2015 Q1	$779K	Hold	4	–	–	0.21%	62
2014 Q4	$825K	Hold	4	–	–	0.18%	61
2014 Q3	$619K	Hold	4	–	–	0.14%	68
2014 Q2	$995K	Hold	4	–	–	0.17%	63
2014 Q1	$1.22M	Hold	4	–	–	0.19%	69
2013 Q4	$1.18M	Buy	+4	New	+$1.75M	0.17%	69

Other funds holding ERNA

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Callahan Advisors Houston, Texas $1.2B AUM 22.34% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Manatuck Hill Partners's ERNA Position: Q4 2016 in Review

Manatuck Hill Partners sold out of Eterna Therapeutics (ERNA) in Q4 2016, closing a stake of 1 share — an estimated $95K sold.

Manatuck Hill Partners first reported a position in ERNA in Q4 2013 and held it in 12 quarters. The position peaked at $1.22M in Q1 2014. 8 funds tracked by Wall St. Rank hold ERNA as of Q4 2016.

Manatuck Hill Partners reported no remaining Eterna Therapeutics position as of Q4 2016 after selling out during the quarter.
Manatuck Hill Partners sold 1 Eterna Therapeutics share in Q4 2016, an estimated $95K.
Manatuck Hill Partners first reported a position in Eterna Therapeutics in Q4 2013 and held it in 12 quarters.
Manatuck Hill Partners's Eterna Therapeutics position peaked at $1.22M in Q1 2014.
8 funds tracked by Wall St. Rank held Eterna Therapeutics as of Q4 2016.

Based on Manatuck Hill Partners's 13F filing for Q4 2016, filed 14 Feb 2017.